Abstract:Safely and efficiently controlling gene expression is a long-standing goal of biomedical research, and the recently discovered bacterial CRISPR/Cas system can be harnessed to create powerful tools for epigenetic editing. Current state-of-the-art systems consist of a deactivated-Cas9 nuclease (dCas9) fused to epigenetic effector motifs/domains, along with a guide RNA (gRNA) which defines the genomic target. Such systems have been used to safely and effectively silence or activate a specific gene target under a variety of circumstances. Adeno-associated virus (AAV) vectors are the therapeutic platform of choice for delivery of genetic cargoes; nevertheless, their small packaging capacity is not suitable for the delivery of large constructs, including most CRISPR/dCas9-effector systems. To circumvent this, many AAV-based CRISPR/Cas tools are delivered separately from two viral cassettes. However, this approach requires higher viral payloads and usually is less efficient. Here we develop a compact dCas9-based repressor system packaged within a single, optimized AAV vector. The system uses a smaller dCas9 variant derived from Staphylococcus aureus (Sa). A novel repressor was engineered by fusing the small transcription repression domain (TRD) from MeCP2 with the KRAB repression domain. The final dSaCas9-KRAB-MeCP2(TRD) construct can be efficiently packaged, along with its associated gRNA, into AAV particles. Using reporter assays, we demonstrate that the platform is capable of robustly and sustainably repressing the expression of multiple genes-of-interest, both in vitro and in vivo. Most relevantly, we successfully silenced APOE, the primary genetic risk factor for late onset Alzheimer disease (LOAD). This new platform will broaden the CRISPR/dCas9 toolset available for transcriptional manipulation of gene expression in research and therapeutic settings.

Characterisation of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina

Comparison of CRISPR/Cas endonucleases for in vivo retinal gene editing

In Situ Gene Therapy Via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation.

Direct delivery of Cas9 or base editor protein and guide RNA complex enables genome editing in the retina

Safety and efficacy of CRISPR-mediated genome ablation of VEGFA as a treatment for choroidal neovascularization in nonhuman primate eyes

Unleashing the potential of CRISPR multiplexing: Harnessing Cas12 and Cas13 for precise gene modulation in eye diseases

Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice

cRGD-modified hybrid lipopolymeric nanoplexes for gene editing in the posterior segment of the eye

Alleviation of neurological disease by RNA editing

Viral delivery of compact CRISPR-Cas12f for gene editing applications

Reduced Expression of VEGF-A in Human Retinal Pigment Epithelial Cells and Human Muller Cells Following CRISPR-Cas9 Ribonucleoprotein-Mediated Gene Disruption

CRISPR/Cas9 mediated specific ablation of vegfa in retinal pigment epithelium efficiently regresses choroidal neovascularization

Therapeutic In Vivo Gene Editing Achieved by a Hypercompact CRISPR‐Cas12f1 System Delivered with All‐in‐One Adeno‐Associated Virus (Adv. Sci. 19/2024)

CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration

AAV-mediated in vivo genome editing in vascular endothelial cells.

CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

Targeted gene silencing in the nervous system with CRISPR-Cas13

Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration

Leverage of nuclease-deficient CasX for preventing pathological angiogenesis

Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders